Optimal balance of benefit versus risk for tafenoquine in the treatment of Plasmodium vivax malaria

Abstract A single 300 mg dose of tafenoquine (an 8-aminoquinoline), in combination with a standard 3-day course of chloroquine, is approved in several countries for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged ≥ 16 years. Despite this, questions have arisen o...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Raman Sharma, Hema Sharma, Siôn Jones, Isabelle Borghini-Fuhrer, Gonzalo J. Domingo, Rachel A. Gibson, Katie Rolfe, Lionel Tan, Ioana Gabriela Fiţa, Chao Chen, Panayota Bird, Anup Pingle, Stephan Duparc
Format:	Artigo
Jezik:	Inglês
Izdano:	BMC 2024-05-01
Serija:	Malaria Journal
Teme:	Plasmodium vivax malaria Radical cure Tafenoquine Benefit–risk
Online dostop:	https://doi.org/10.1186/s12936-024-04924-z
Oznake:	Označite Brez oznak, prvi označite!